Agilent Biocare Deal Adds A Faster-Growing Asset

Agilent opened the week with a deal aimed at strengthening its pathology portfolio, agreeing to acquire Biocare Medical. The company said it has entered into a definitive agreement to buy Biocare for $950 million in cash, adding a clinical pathology business that brings immunohistochemistry, in situ hybridization, and fluorescence in situ hybridization products used across oncology and broader pathology workflows. This is not a science experiment in search of a business model. It is a tuck-in acquisition aimed at a category Agilent already knows well, with a target that fits directly into the lab and pathology ecosystem it already serves.

Biocare arrives with real operating traction, which tends to make acquisition math look a lot less theoretical. Agilent said Biocare has more than 300 specialized antibodies, has delivered annual double-digit revenue and profit growth since 2021, and generated more than $90 million of revenue in 2025. That gives the deal a nice investor quality: Agilent is not buying a promise wrapped in a slide deck, but a business that already sells products, grows at a healthy clip, and gives the larger platform more ways to win in pathology. In a market that usually appreciates proof over poetry, Biocare brought both a portfolio and a pulse.

Agilent said the acquisition should expand its pathology portfolio, strengthen its immunohistochemistry offering, broaden its reach across research and clinical customers, and accelerate menu development by pairing Agilent’s global operations with Biocare’s strong U.S. commercial presence. Agilent said the transaction is expected to be accretive to its top-line growth rate, margin profile, and non-instrument revenue mix in the first year, with EPS accretion expected about 12 months after closing. That makes the deal easier for investors to follow, because the case for it runs through revenue mix, margins, and earnings rather than vague strategic theater.

Agilent came into this announcement off a first quarter in which revenue rose 7.0% to $1.80 billion, non-GAAP EPS increased to $1.36, and the company raised its fiscal 2026 revenue outlook to $7.3 billion to $7.5 billion. Against that backdrop, the Biocare deal comes across as a proactive growth move by a company that was already putting up a decent quarter. The deal is expected to close by no later than Agilent’s fourth fiscal quarter of 2026, subject to customary conditions and regulatory approvals, and Biocare will join Agilent’s Life Sciences and Diagnostics Markets Group. For now, the transaction looks like a fairly clean use of capital by a company that sees room to keep improving an area where it already has credibility.

Disclaimer: This content is for informational and entertainment purposes only and does not constitute financial or investment advice. The information provided may be outdated or contain inaccuracies. Always conduct your own due diligence and consult a licensed financial advisor before making investment decisions. Investing involves risk, including the potential loss of principal. Unless explicitly stated otherwise, neither Equiscreen, LLC nor its beneficial owners hold any financial interest in the companies mentioned in our articles, and we do not receive compensation for including them. Equiscreen, LLC and its beneficial owners may buy or sell securities of any company referenced in our content at any time and without prior notice, and nothing published by Equiscreen, LLC should be interpreted as a recommendation to buy, sell, or hold any security. Any paid content or income-related materials will be clearly identified as “Sponsored” or “Advertorial,” and corresponding income disclosures can be found at the bottom of the page. For additional information, please contact [email protected].

Top Gainers

Top Losers

U.S. Commodities

2234 N Federal Hwy # 1022
Boca Raton, FL 33431

(561) 264-5726